Patients undergoing joint replacement surgery are the first target group for NASOFLORE.
More than 10 million people around the world have had a joint replacement and that number is expected to quadruple by 2030.
Staphylococcus aureus is the cause of more than 2000 joint replacement infections in France each year and these infections require significant medical and surgical treatment, generating excessive cost overages.
Despite great progress in the ways patients are treated, the prevalence of these infections is not going down. The Nasoflore approach represents a real source of hope for the future.